Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 2/20 | 0.56 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.56 |
| ▸ | CES2 | O00748 | 1/20 | 0.46 |
| ▸ | DDR1 | Q08345 | 9/20 | 0.42 |
| ▸ | SLC13A3 | Q8WWT9 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.40 |
| ▸ | ACLY | P53396 | 1/20 | 0.40 |
| ▸ | RHOC | P08134 | 2/20 | 0.40 |
| ▸ | RHOA | P61586 | 2/20 | 0.40 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL630414 | 0.87 | PTPN1 (0.66) | GSK3BPTPN1CES2GAAP2RX1 | |
| SCHEMBL27873685 | 0.83 | DDR1 (0.48) | CES2DDR1SLC13A3MEN1PLA2G1B | |
| SCHEMBL1198757 | 0.81 | GSK3B (0.61) | GSK3BPTPN1 | |
| SCHEMBL766117 | 0.81 | NOTUM (0.58) | GSK3BPTPN1CES2DDR1MEN1 | |
| SCHEMBL865889 | 0.81 | PTPN1 (0.58) | GSK3BPTPN1CES2DDR1HDAC3 | |
| SCHEMBL12187811 | 0.79 | PTPN1 (0.56) | GSK3BPTPN1CES2GAAHDAC6 | |
| SCHEMBL7786074 | 0.79 | GSK3B (0.56) | GSK3BPTPN1CES2MEN1KMT2A | |
| SCHEMBL8911364 | 0.79 | DDR1 (0.40) | CES2DDR1SLC13A3MEN1PLA2G1B | |
| SCHEMBL1792413 | 0.78 | CES2 (0.52) | CES2DDR1SLC13A3MEN1PLA2G1B | |
| SCHEMBL978457 | 0.78 | TPMT (0.61) | CES2DDR1ACLYHDAC3HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2419413-B1 | DERIVATIVES OF N-ACYL-N'-PHENYLPIPERAZINE USEFUL (INTER ALIA) FOR THE PROPHYLAXIS OR TREATMENT OF DIABETES | TAKEDA PHARMACEUTICAL (JP) | 2016-11-23 | — | — | EP | disclosed |
| US-8853215-B2 | Derivatives of N-acyl-N′-phenylpiperazine useful (inter alia) for the prophylaxis or treatment of diabetes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-10-07 | — | — | US | disclosed |
| US-20120071489-A1 | DERIVATIVES OF N-ACYL-N'-PHENYLPIPERAZINE USEFUL (INTER ALIA) FOR THE PROPHYLAXIS OR TREATMENT OF DIABETES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-22 | — | — | US | disclosed |
| US-5717116-A | TREATING A MIXTURE OF PHENYLHALOGENOMETHYLCARBINOLS WITH A LIPASE IN THE PRESENCE OF A CARBOXYLATE FOLLOWED BY CYCLIZATION WITH A BASE | SUMIKA FINE CHEMICALS COMPANY, LIMITED (JP) | 1998-02-10 | — | — | US | disclosed |
| EP-0735142-A2 | Process for producing (R)-styrene oxides | SUMIKA FINE CHEMICAL COMPANY, LTD. (JP) | 1996-10-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071489-A1 | DERIVATIVES OF N-ACYL-N'-PHENYLPIPERAZINE USEFUL (INTER ALIA) FOR THE PROPHYLAXIS OR TREATMENT OF DIABETES | RBP4, RBP1, FABP4 | GSK3B 4719/4885PTPN1 2423/4885CES2 3053/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.